These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36105663)

  • 1. Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
    Raina R; Houry A; Rath P; Mangat G; Pandher D; Islam M; Khattab AG; Kalout JK; Bagga S
    Drug Healthc Patient Saf; 2022; 14():147-159. PubMed ID: 36105663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tolvaptan, a vasopressin V
    Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
    Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies.
    Chebib FT; Zhou X; Garbinsky D; Davenport E; Nunna S; Oberdhan D; Fernandes A
    Kidney Med; 2023 Jun; 5(6):100639. PubMed ID: 37250503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
    Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Lee J; Hoke ME; Estilo A; Sergeyeva O
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):48-58. PubMed ID: 33376102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA
    Drugs; 2019 Feb; 79(3):303-313. PubMed ID: 30689194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
    Kramers BJ; van Gastel MDA; Boertien WE; Meijer E; Gansevoort RT
    Am J Kidney Dis; 2019 Mar; 73(3):354-362. PubMed ID: 30578153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
    Alpers DH; Lewis JH; Hunt CM; Freston JW; Torres VE; Li H; Wang W; Hoke ME; Roth SE; Westcott-Baker L; Estilo A
    Am J Kidney Dis; 2023 Mar; 81(3):281-293.e1. PubMed ID: 36191725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
    Torres VE; Devuyst O; Chapman AB; Gansevoort RT; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Sergeyeva O;
    Am J Nephrol; 2017; 45(3):257-266. PubMed ID: 28166521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
    Liu F; Feng C; Shen H; Fu H; Mao J
    Kidney Dis (Basel); 2021 Sep; 7(5):343-349. PubMed ID: 34604341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
    Muto S; Okada T; Shibasaki Y; Ibuki T; Horie S
    Clin Exp Nephrol; 2021 Sep; 25(9):1003-1010. PubMed ID: 34089122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Per-Treatment
    Mallett AJ; Perrone RD; Rangan G; Hawley C; El-Damanawi R; Hiemstra TF; Arellano CT; Lee J; Torres VE
    Kidney Int Rep; 2021 Apr; 6(4):1032-1040. PubMed ID: 33912753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA; Keating GM
    Drugs; 2015 Oct; 75(15):1797-806. PubMed ID: 26407729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolvaptan in ADPKD Patients With Very Low Kidney Function.
    Torres VE; Gansevoort RT; Perrone RD; Chapman AB; Ouyang J; Lee J; Japes H; Nourbakhsh A; Wang T
    Kidney Int Rep; 2021 Aug; 6(8):2171-2178. PubMed ID: 34386666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
    Casteleijn NF; Blais JD; Chapman AB; Czerwiec FS; Devuyst O; Higashihara E; Leliveld AM; Ouyang J; Perrone RD; Torres VE; Gansevoort RT;
    Am J Kidney Dis; 2017 Feb; 69(2):210-219. PubMed ID: 27856088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics associated with 1-year tolvaptan efficacy in autosomal dominant polycystic kidney disease with a wide range of kidney functions.
    Murakami T; Nishimura K; Ono H; Ueta S; Shibata E; Kishi S; Tamaki M; Miya K; Shima H; Tashiro M; Inoue T; Kawahara K; Nagai K; Abe H; Minakuchi J; Doi T
    J Med Invest; 2020; 67(3.4):315-320. PubMed ID: 33148908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study.
    Lai S; Mangiulli M; Perrotta AM; Gigante A; Napoleoni L; Cipolloni E; Mitterhofer AP; Gasperini ML; Muscaritoli M; Cianci R; Giovannetti A; Falco F; Mastroluca D; Mazzaferro S
    Curr Vasc Pharmacol; 2021; 19(5):556-564. PubMed ID: 32957887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.